AnaptysBio Deploys E-WorkBook to Manage Data Generated Using Its SHM-XEL™ Antibody Discovery and Optimization Platform
Complete the form below to unlock access to ALL audio articles.
IDBS, has announced that AnaptysBio, Inc., an emerging U.S. biotechnology company, has adopted IDBS' E-WorkBook Suite to manage research data generated using its SHM-XEL™ antibody discovery and optimization platform. Therapeutic antibodies are widely regarded as the fastest growing segment of the pharmaceutical industry.
AnaptysBio is the leader in the in vitro application of somatic hypermutation (SHM) for antibody discovery and optimization. SHM is the body's natural process for generating potent antibodies to fight disease. AnaptysBio's SHM-XEL™ platform couples SHM with mammalian cell expression, secretion and display, deep sequencing, and flow cytometry to generate antibodies for therapeutic applications through a process of natural evolution and high-throughput selection.
This versatile platform is being used for both discovery of new antibodies and optimization of existing antibodies to generate product candidates for its internal pipeline and partners.
E-WorkBook provides AnaptysBio with searchable, scalable and secure information management that is applicable across their business, improving internal and external collaboration, process efficiency and data consistency. E-WorkBook enables AnaptysBio to secure unparalleled context with their data, to search, annotate and report swiftly on their results and to meet their scientific goals.
"Research productivity is a priority for industry, including the ability to timely and comprehensively collect, retrieve and analyze data," said Tom Smart, Chairman and CEO of AnaptysBio. "We look forward to utilizing E-WorkBook to provide us with greater visibility and control of data generated using our SHM-XEL™ platform, and enhance our ability to search, retrieve and generate reports for scientific analysis."
"E-WorkBook applications enable customers to extract maximum information value from their enterprise data and is a foundation for pioneering therapeutic research such as SHM," said Neil Kipling, founder and CEO of IDBS. "AnaptysBio's technology represents a unique and innovative approach that offers the promise of expanding treatment options for a wide range of diseases, and we are delighted to be supporting their research."
